drugset / Trial / NCT06487702
A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label，multi-center, phase Ib/II study, aiming to evaluate the efficacy and safety of Fruquintinib combined With Cadonilimab (AK104) and Tegafur，Gimeracil and Oteracil Potassium in patients with locally advanced or metastatic esophageal squamous cell carcinoma after the failure of first-line treatments.
Timeline
- Start
- 2024-07-10
- Primary completion
- 2026-06-10
- Completion
- 2027-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Candonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Fruquintinib | Small molecule | 2 mg | Oral |
| Subject | Fruquintinib | Small molecule | 3 mg | Oral |
| Subject | S-1 | Small molecule | 30 mg | — |
| Subject | S-1 | Small molecule | 40 mg | — |
| Subject | S-1 | Small molecule | 50 mg | — |